A phase II, open label, multicenter study of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies (follicular lymphoma, mantle cell lymphoma, diffuse large cell lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukemia).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2011

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AT 101 (Primary)
Indications B-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Ascenta Therapeutics

Most Recent Events

01 Sep 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
15 Nov 2007 Status changed from in progress to completed.
11 May 2007 Status changed from recruiting to in progress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight